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Neuromyelitis optica spectrum disorders (NMOSD) are autoantibody mediated chronic
inflammatory diseases. Serum antibodies (Abs) against the aquaporin-4 water channel
lead to recurrent attacks of optic neuritis, myelitis and/or brainstem syndromes.
In some patients with symptoms of NMOSD, no AQP4-Abs but Abs against
myelin-oligodendrocyte-glycoprotein (MOG) are detectable. These clinical syndromes
are now frequently referred to as “MOG-encephalomyelitis” (MOG-EM). Here we give an
overview on current recommendations concerning diagnosis of NMOSD and MOG-EM.
These include antibody and further laboratory testing, MR imaging and optical coherence
tomography. We discuss therapeutic options of acute attacks as well as longterm
immunosuppressive treatment, including azathioprine, rituximab, and immunoglobulins.
Keywords: neuromyelitis optica, aquaporin-4 antibodies, MOG-encephalomyelitis, diagnostic criteria,
immunosuppressive treatment
INTRODUCTION
Neuromyelitis optica spectrum disorders (NMOSD) are rare chronic inflammatory central nervous
system diseases distinct from multiple sclerosis (MS). The French term “neuro-myélite optique
aiguë,” whichmay be translated as “neuromyelitis optica acuta” was first used byDevic in 1894 (1, 2).
In the majority of patients with NMOSD, autoantibodies (Abs) against the astrocyte aquaporin-4
(AQP4) water channel are detectable and patients typically suffer from recurrent attacks of severe
optic neuritis or/and myelitis (3–7). In rarer cases, brainstem and brain involvement e.g., area
postrema syndrome or diencephalic syndrome can occur (8, 9). Patients also frequently suffer
from burdensome symptoms like pain, headache, depression, fatigue, and sleep disorders (10–
14). Despite treatment, recovery from attacks is often incomplete and disease remission rarely
occurs (15, 16). Thus, in relapsing NMOSD, which account for approximately 80–85% of cases,
neurologic deficits frequently accumulate during the disease course. Patients without long-term
immunosuppressive therapy have a worse prognosis with a higher mortality rate (17). Disease
onset ranges between 4 and 88 years with a mean age at onset of 39 years (18–21). Women are
disproportionately more often affected and, particularly in AQP4-seropositive patients, female to
male-ratio can reach up to 10:1 (19, 22, 23). In 20–30% of patients, depending on the assay used,
AQP4-Abs are not detectable (24, 25). Whether AQP4-Ab positive and AQP4-Ab negative diseases
are varieties of the same disorder or rather reflect different disease entities is a topic of ongoing
research (26–28).
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Recently, various publications described the detection of
serum-Abs against myelin-oligodendrocyte-glycoprotein (MOG)
in AQP4-Ab negative NMOSD patients including pediatric
cohorts and few patients with MS (29–41). In the past,
MOG-Abs were particularly described in acute disseminated
encephalomyelitis (ADEM), an inflammatory CNS disorder that,
if it has an pediatric onset, is mostly monophasic and has a
favorable outcome in the majority of cases (42, 43). MOG is
a glycoprotein localized on the surface of the myelin sheath
as well as of the cell body and processes of oligodendrocytes
(44, 45). According to the revised 2015 NMOSD diagnostic
criteria (46), diseases with or without evidence of AQP4-
Abs as well as disorders with MOG-Abs can be assigned to
the NMO spectrum. Although there are numerous overlaps
in clinical presentation and imaging findings with NMOSD
with and without AQP4-Ab, MOG-Ab-associated disease is
more and more considered a disease entity in its own (47).
Previous studies on NMOSD might have included patients with
MOG-Abs and therefore overlapping features could have been
reported in these studies. Various terms are used to describe
the disease such as “MOG-antibody related disorder,” “MOG-
associated disease,” “MOG antibody disease,” “MONEM” or
“MOG-encephalomyelitis (MOG-EM)”(40, 47–50). Hereafter,
we use the term “MOG-EM,” as it reflects the relevant symptoms
of the disease and is used in several recent publications, e.g., (49).
Although ADEM can also be accompanied by MOG-Abs (51), in
this manuscript we do not regardMOG-Ab positive patients with
ADEM-phenotype as part of the “MOG-EM” due to their distinct
clinical characteristics. To date, the relevance of MOG-Abs and
their nosologic categorization is a topic of current discussion and
under further investigation (47, 52, 53).
To give an overview on diagnosis and treatment
recommendations in NMOSD and MOG-EM, we here describe
our own clinical experiences and give a review on the current
literature using the Pubmed online database. We used the search
terms “neuromyelitis optica,” “neuromyelitis optica spectrum
disorder,” “MOG,” aquaporin-4 antibodies,” “MRI,” “diagnostic
criteria,” “therapy,” and combinations of these. To find all
relevant publications, we did not restrict the year of publication;
however, most reports originate from the last 5 years.
DIAGNOSIS
In NMOSD and MOG-EM, most common symptoms are
optic neuritis and longitudinally extensive transverse myelitis
(LETM). Signs of brainstem affection like persistent hiccup,
nausea or vomiting should explicitly be asked for as they are
often attributed to other reasons and are therefore not reported
spontaneously by the patient. Rarer clinical manifestations of
NMOSD comprise narcolepsy, acute diencephalic syndrome
or muscle affection (54, 55), while in MOG-EM extraneural
involvement such as reversible paraspinal muscle hyperintensity
have been described, as well as MOG-Abs in combined central
and peripheral demyelination syndromes (56, 57).
Like NMOSD, MOG-EM can affect optic nerve, spinal cord,
and brainstem. However, some studies showed histopathological
differences between NMOSD and MOG-EM (58, 59). AQP4-Abs
bind to water channels located on astrocytes, whereas MOG-
Abs target myelin-forming oligodendrocytes (53). Both types of
antibodies may lead to disturbances of the integrity of blood
brain barrier and to CNS inflammation (53, 60). However, while
inflammation in MOG-EM primarily results in demyelination,
demyelination in NMOSD seems to be a secondary phenomenon
following astrocytic damage (61, 62).
In patients with AQP4-Abs, the most frequent symptoms at
onset are optic neuritis in 37-54% of the patients, and LETM
in 30–47% of the patients (26, 63, 64). In patients with MOG-
Abs, optic neuritis was the first clinical manifestation in 33–
64% whereas myelitis occurred in 18–33% of the patients as
initial symptom (33, 48, 65). Also during the further course of
the disease, optic neuritis seems to be more frequent in MOG-
EM than in NMOSD with myelitis being less common (29,
66). However, in population-based ON studies and unselected
cohorts of patients with ON, both the prevalence of AQP4-Abs
andMOG-Abs is low (67–69). In MOG-EM, cases of encephalitis
and seizures were described whereas these symptoms are rare
in NMOSD (70–72). MOG-EM differs from NMOSD in further
clinical characteristics e.g., in gender ratio and age at onset.
In (relapsing) NMOSD, up to 90% of the patients are female,
whereas the proportion of male patients in MOG-EM ranges
from 43 to 63% (22, 26, 29–31, 73). The published mean age
at onset ranges from 27 and 37 years in patients with MOG-
EM (29–31, 73) and between 30 and 46 years for patients with
NMOSD (19, 26, 29–31, 73). At onset, patients with MOG-Abs
are more likely to suffer from simultaneous or rapidly sequential
optic neuritis and LETM compared to patients with AQP4-
Abs (31). In AQP4-Ab positive NMOSD, most patients (80–
90%) have a relapsing disease course (26, 73, 74). In MOG-EM,
monophasic disease course is considered to be more frequent,
however, the duration of follow-up and a referral bias might
have influenced these results (33, 73–76). Some studies showed
lower disability outcomes, measured by the Expanded Disability
Status Scale (EDSS), in MOG-EM than in NMOSD, suggesting
a presumably more favorable prognosis (29–31, 73). However,
long-term data from MOG-EM are scant. Whereas spinal cord
lesions frequently affect cervicothoracic segments in NMOSD,
they tend to be localized in thoracolumbar parts of the spinal cord
including the conus in MOG-EM (29, 31). Table 1 summarizes
the epidemiological and clinical features in NMOSD and MOG-
EM.
Antibody Diagnosis
A central component of diagnostics in NMOSD andMOG-EM is
the detection of Abs in serum. AQP4-Abs were firstly described
in 2004 and made it possible to differentiate NMOSD from MS
(78). The best detection rates are provided by cell-based assays
(CBA) (24, 32, 79, 80). In NMOSD, the sensitivity of these assays
ranges between 80 and 100%, whereas specificity varies between
86 and 100% (24). Contrarily, enzyme-linked immunosorbent
assays (ELISA) may lead to false-positive results and should not
be used as sole method (81–83).
Specific antibodies against MOG are detectable in pediatric
patients with acute disseminated encephalomyelitis (ADEM)
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TABLE 1 | Epidemiological and clinical features in NMOSD and MOG-EM.
AQP4-Ab positive NMOSD MOG-EM
Mean age at onset [range] 40–46 years (26, 31, 73) 27–37 years (30, 73)
Female to male ratio [range] 7.2:1–10:1 (26, 29, 31, 73) 1:1.6–1.3:1 (29–31)
Median EDSS at last follow-up [range] 4.0–5.8 (29, 31, 73) 0–1.5 (29, 31, 73)
Frequency of coexisting autoimmune diseases 16–45% (31, 73) 6–11% (31, 73)
Localization of optic nerve lesions orbital, chiasm (77) orbital, canalicular, intracranial (77)
Features of optic neuritis OCT: prominent RNFL thinning (77) Severe optic nerve swelling at onset (77); frequently simultaneous
or rapidly sequential optic neuritis and LETM (31)
Localization of spinal cord lesions Cervical, thoracic (29) Thoracic, lumbar (29), involving conus (31)
MRI brain lesions More frequently lesions in medulla oblongata
and area postrema (65)
More frequently ADEM-like brain lesions, deep gray matter lesions
(31), lesions in pons, thalamus (65)
(84–86). In MS patients, MOG-Abs were described for the first
time at the beginning of the 1990s (87). Further studies confirmed
these findings (88–90). Later, MOG-Abs were found in AQP4-
Ab negative patients with clinical symptoms of NMOSD (91,
92). Like in NMOSD, CBA are the current gold standard to
detect MOG-Abs (39, 49). Formerly used assays had a low MOG
specificity, which led to high rates of false positive results (39,
49). Therefore to date, cell-based assays targeting at full-length
human MOG and the use of IgG1-specific secondary antibodies
is highly recommended to avoid cross-reactivity with IgM and
IgA antibodies (39, 49).
AQP4- and MOG-serostatus and Ab-level may change during
the disease course. In patients with suspected NMOSD or MOG-
EM without initial evidence for seropositivity, further Ab-testing
may be required during the course of the disease, especially
during acute attacks and intervals without treatment. AQP4-
Abs usually stay detectable during remission, although the titer
may be lower with immunosuppression (some patients even
seroconvert to negative over time) and during acute attacks
(93). In MOG-EM, approximately 80% of patients with evidence
of MOG-Abs during acute attack remained seropositive during
remission (33). However, the rate was lower with only 50%
of patients remaining seropositive in a study from Korea (76).
As in AQP4-Ab positive NMOSD, MOG-Ab serum titers are
significantly higher during acute attack than during remission
(33). In some studies, Ab-titers were associated with relapses
and treatment status (32, 93, 94). However, the level of AQP4-
titer does not seem to be predictive for long term disease course
(95), and AQP4-Ab serostatus is not predictive of response to
immunotherapy (96). Testing of patients with progressive MS
for MOG antibodies is not warranted under most circumstances
(97).
Testing CSF for AQP4- or MOG Abs is not routinely
recommended as it does not seem to provide an additional benefit
for diagnosing NMOSD orMOG-EM (98, 99). AQP4-Abs in CSF
can be detected in only 70% of Aqp4-Ab seropositive patients and
in none of the AQP4 seronegative patients (100). Like AQP4-Abs,
MOG-Abs are produced mainly extrathecally and are therefore
less frequent in CSF than in serum (32).
Comorbidity with other autoimmune disorders is frequent
in NMOSD patients (101–105). Therefore, further tests
for autoantibodies should comprise Abs associated with
rheumatologic diseases e.g., ANA, ANCA, Anti-ds-DNA-Abs,
and lupus anticoagulant. If there are clinical signs in anamnesis
or examination, Ab testing for myasthenia gravis, coeliac disease,
or paraneoplastic disorders should be performed (101, 106–110).
In MOG-EM, the frequency of coexistent autoimmune diseases
seems to be lower than reported for AQP4-Ab positive patients
(33, 66).
Further Laboratory Diagnosis
Other laboratory tests are recommended to diagnose coexisting
autoimmune disorders and to exclude other differential
diagnoses. Next to routine laboratory tests, this includes
differential blood count, blood sedimentation, folic acid,
and vitamin B12 (111). To exclude sarcoidosis which is a
relevant differential diagnosis as it can also manifest with optic
neuropathy or myelopathy (112, 113), tests on hypercalcemia
and hypercalciuria, interleukin-2-rezeptor (sIL-2 R), and
angiotensin-converting enzyme (ACE) should be performed
(112, 114).
Analysis of cerebrospinal fluid (CSF) might be helpful to
exclude other diagnoses, especially to differentiate between
NMOSD/MOG-EM and MS. In NMOSD, white cell counts
were elevated in up to 50% of the patients, especially during
acute attack, and in approximately 10% of the patients CSF-
restricted oligoclonal IgG bands (OCB) can be detected (73,
100). Increased CSF/serum albumin ratio as a marker of
dysfunction of blood brain barrier was found in 51% of NMOSD
patients (100).
In MOG-EM, elevated white cell counts were found in 25–
70% of the patients, whereas there was no differentiation between
tests during acute attack and remission. (33, 66, 73). Like in
NMOSD, OCB were detected in 10% of the MOG-EM patients
and CSF/serum albumin ratio was elevated in 32% (33, 66, 73).
Magnetic Resonance Imaging
Next to the AQP4-Abs, MRI is an essential element to diagnose
NMOSD. It helps to differentiate NMOSD from MS and other
CNS disorders (115).
Spinal cord imaging was already included in the 2006
NMO diagnostic criteria (116). These criteria require MRI
spinal cord lesion extending over ≥3 vertebral segments (116).
However, in 15 percent of myelitis attacks, spinal cord lesions
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do not extend over ≥3 vertebral segments which may lead to
misdiagnosis or delayed diagnosis of NMOSD (117). Typical
NMOSD lesions are located centrally in the spinal cord and
involve more than the half of spinal cord cross-section area
(118). It was suggested by Yonezu et al.(119) that “bright
spotty lesions” are characteristic for NMOSD and might reflect
microcystic defects of the spinal cord (113). The specificity
of this sign however still needs to be confirmed in further
studies. The interval between clinical symptoms and the MRI
is influencing the MRI presentation of LETM lesions. They
may not be present from relapse onset and may change into
multiple short lesions or into spinal cord atrophy during the
disease course (120, 121). Hence, there is the risk miss a typical
MRI presentation of the LETM when the MRI is performed
too early or too late (72). Other causes for longitudinally
extensive spinal cord LETM lesions include sarcoidosis or
spondylotic myelopathy or rarely MS and need to be considered
(112, 122, 123). In addition longitudinally extensive myelitis
lesions were recently described in patients with symptoms
of meningitis, encephalitis and/or myelitis that were tested
positive for glial fibrillary acidic protein (GFAP)-IgG (124–
126).
Brain MRI at first presentation often shows no lesions
which has been the reason to define normal brain MRI as
one NMO diagnostic criterion in 2006 (116). However, more
recent studies showed that the presence of cerebral lesions is not
uncommon in the clinical course of NMOSD (127–129). Hence,
the NMOSD 2015 diagnostic criteria have incorporated findings
of cerebral MRI and define NMOSD-typical brain lesions (46).
These lesions can be located at the periependymal surfaces of
the third and fourth ventricle, in the area postrema, corpus
callosum, hypothalamus or thalamus (130–132). In addition,
subcortical or deep white matter lesions are possible. Meningeal
enhancement has been reported in some cases, although this
does not appear to be a very frequent imaging finding in
NMOSD (133). Orbital MRI may show increased T2 signal and
gadolinium enhancement of the optic nerve as signs of an optic
neuritis. This can be helpful to diagnose MOG-EM or NMOSD
in patients without AQP4-Abs (46, 77, 131, 134, 135). Chiasmal
involvement is more common in AQP4-NMOSD than in MOG-
EM (134).
A study by Ramanathan et al. showed no MRI brain
lesions in a large proportion of MOG-EM patients (66).
Conversely, other authors found supra- and infratentorial
MRI abnormalities in 40–50% of the patients (33, 65). Brain
imaging allows to distinguish MOG-EM from MS, but shows
many overlaps with AQP4-Ab NMOSD (136–138). Moreover,
a relevant number of patients show pathologic findings in
MRI of optic nerve and spinal cord, comparable to NMOSD
patients (33, 74). However, one study revealed a more frequent
occurrence of optic nerve head swelling and retrobulbar
affection of the optic nerve in MOG-EM compared to NMOSD
(134).
Figure 1 shows MRI features of NMOSD and MOG-EM.
Studies investigating non-conventional MR imaging in NMOSD
will not be reviewed further as they currently lack implications
for clinical management (139–141).
Optical Coherence Tomography
Optical coherence tomography is an interferometric technique
using near infra-red backscattered light to generate high
resolution images of the retina and its various layers, that is
increasingly applied in various neuroimmunological disorders
(142–148). OCT displays severe damage to the retinal nerve fiber
layer and the ganglion cell layer following attacks of optic neuritis
in both AQP4 NMOSD andMOG-EM that correlates with visual
function and quality of life (149–158). It is currently a matter of
debate if retinal damage following optic neuritis is equally severe
in AQP4-NMOSD and MOG-EM (75, 77, 152, 159–162) and
to which extent structural retinal alterations occur in NMOSD
independently of optic neuritis attacks (143, 157, 163–167).
Although the utility of OCT in patient management requires
further investigation, it may help quantify the extent of structural
retinal damage following optic neuritis attacks and thus hopefully
inform treatment decisions (168–170), and support differential
diagnosis in the near future.
Diagnostic Criteria
Current NMOSD diagnostic criteria were published by the
International Panel for NMO Diagnosis in 2015 (46) and were
aimed at taking recent advances in the field following the 2006
Wingerchuk criteria into consideration (116). They differentiate
between NMOSD with AQP4-Abs and NMOSD without AQP4-
Abs or unknown AQP4-Ab status.
In the case of positive AQP4-Ab status, one of the following
clinical core symptoms is required:
1. Optic neuritis
2. Acute myelitis
3. Area postrema syndrome: episode of otherwise unexplained
hiccups or nausea and vomiting
4. Acute brainstem syndrome
5. Symptomatic narcolepsy or acute diencephalic clinical
syndrome with NMOSD-typical diencephalic MRI lesions
6. Symptomatic cerebral syndrome with NMOSD-typical brain
lesions
NMOSD-typical brain lesions may involve the dorsal medulla,
especially the area postrema, the periependymal surfaces of the
third or fourth ventricle, the hypothalamus, thalamus, the corpus
callosum, cerebral peduncles, and the internal capsule. Moreover,
subcortical or deep white matter lesions and corticospinal tract
lesions are possible. Alternative diagnoses e.g., MS, sarcoidosis,
infectious or neoplastic diseases have to be excluded.
In patients without evidence of AQP4-Ab two of the above
mentioned core clinical characteristics are necessary for NMOSD
diagnosis. At least one of these core clinical characteristics has to
be ON, LETM or area postrema syndrome. Moreover, supportive
characteristics in cerebral, spinal cord or optic nerve MRI are
required. These are
- normal brain MRI or long optic nerve lesions with increased
T2 signal or gadolinium enhancement of the optic nerve or the
chiasm in patients with ON,
- spinal cord MRI lesion or focal spinal cord atrophy extending
over ≥3 segments in patients with myelitis and
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FIGURE 1 | MRI of patients with AQP4-Ab positive NMOSD and patients with MOG-EM. Severe cervical LETM in a NMOSD AQP+ patient: (a) T2 sagittal and (b) T2
axial of a cervical myelon lesion with ring Gd-Enhancement and T1 hypointense center in (c) T1+Gd sagittal and (d) T1+Gd axial. Bilateral opticusneuritis in a
MOG-EM patient (e) T1+Gd axial and (f) T1+Gd coronar. Unilateral optic neuritis with chiasmal involvement in a NMOSD AQP4+ patient: (g) T1+Gd axial and
(h) T1+Gd coronar. Tumefactive lesion involving the corpus callosum in a NMOSD AQP4+ patient (i–k) T2 axial.
- lesions involving dorsal medulla oblongata/area postrema in
patients with area postrema syndrome
- periependymal brainstem lesions in patients with acute
brainstem syndrome.
Using the 2015 instead of the 2006 criteria led to a significant
increase in the number of patients diagnosed with NMOSD
(138, 171, 172)
For MOG-EM, to date, no evidence based diagnostic criteria
exist. However, NMOSD 2015 diagnostic criteria allow to include
cases of NMOSD associated with other specific autoantibodies
(46).
TREATMENT OF ACUTE ATTACKS
In NMOSD as well as in MOG-EM, acute attacks are usually
treated with 1,000mg intravenous methylprednisolone (IVMP)
for 3–5 days. Jarius et al. showed complete or almost complete
recovery in 50% of IVMP treated MOG-EM attacks (33). In
NMOSD, IVMP led to complete recovery in 17–35% of the
attacks (15, 173). In case of poor response, treatment escalation
with 2,000mg IVMP may improve outcome, for further therapy
escalation plasma exchange (PLEX) or immunoadsorption are
possible (15, 173–175). PLEX and immunoadsorption did
not show a difference in their efficacy in the therapy of
NMOSD attacks (176). They can also be used as first-line
therapy (in particular in myelitis attacks) if response to
methylprednisolone during previous attacks was poor. An early
initiation of PLEX seems to improve the clinical outcome (176,
177).
PREVENTATIVE IMMUNOSUPPRESSIVE
THERAPY
Attacks in NMOSD as well as in MOG-EM are often
characterized by severe neurologic deficits with poor recovery.
Frequently, a relevant disability persists after an attack. However,
there are indications that MOG-EM has a less severe course than
NMOSD and relapse risk depends on Ab status (30, 65, 66).
In some patients with evidence of MOG-Abs, seroconversion
to an Ab- negative status may occur during the disease course
(30, 32, 76).
There is increasing evidence that immunosuppressive therapy
is essential to reduce disease activity and to avoid further attacks.
However, to date no placebo controlled trial has been published
and only one open randomized clinical trial has been performed
(178). Thus, the current treatment paradigm is based on case
series, (retrospective) observational studies as well as expert
opinion. Hereafter, we describe the to-date used treatments in
NMOSD and MOG-EM (179).
Low Dose Prednisone/Prednisolone
Low dose oral corticosteroids are used in many neurologic
diseases. Oral prednisone/prednisolone can be given subsequent
to attack therapy with IVMP in decreasing dose levels and
as comedication during the first months of azathioprine
(AZA) or mycophenolate mofetil (MMF) treatment until
these drugs exert their full efficacy. Possible side effects
are weight gain, hypertension, thrombosis, osteoporosis,
fungal and viral infections, hyperglycemia, gastritis and
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peptic ulcer, psychiatric disturbances and a Cushing
syndrome (180).
Data on long-term treatment with oral
prednisone/prednisolone in NMOSD are limited. A few
studies could show a decrease in ARR by low dose steroid
therapy (181, 182). Moreover, it is known from treatment
experiences with AZA that additional oral prednisone is effective
to reduce disease activity during the first 3–6 months until AZA
reaches its full efficacy.
In MOG-EM, low treatment failure rates were achieved with
oral prednisone (66). The occurrence of relapses during tapering
or after cessation of subsequent oral prednisone after IVMP
attack treatment supports the beneficial effects of corticosteroid
therapy in MOG-EM (33), at least in patients with persistence
of MOG Abs (66). However, due to the known side effects
and the existence of other treatment alternatives, a long-
term therapy with low dose prednisone should be critically
weighed.
Azathioprine
AZA is a purine analog, acts as antimetabolite and inhibits the
differentiation of lymphocytes. Thereby it has antiproliferative
and immunosuppressive effects. It is administered in a dose of
2–3 mg/kg body weight per day and reaches its full effectiveness
after 3–6 months. During the initial period, additional oral
prednisone [1 mg/kg/day] is necessary and can be slowly tapered
when AZA becomes fully effective.
The most important side effect is a bone marrow depression
with anemia, leuko- and/or thrombopenia. The risk of bacterial,
viral or fungal infection is increased. Moreover, elevation of liver
enzymes, nausea or emesis can appear. Rare side effects especially
after long treatment duration include malignomas e.g., of the
skin, and a progressive multifocal leukoencephalopathy (PML).
Furthermore, add-on therapy with prednisone enhances the risk
of side effects, like a diabetogenic metabolic state, thrombosis or
psychiatric symptoms.
Patients with a congenital deficiency of
thiopurinmethyltransferase (TPMT), an enzyme responsible
for metabolisation of AZA, have a high risk of bone marrow
depression. Therefore, it is recommended to test for TPMT-
deficiency in patients with pronounced deterioration of blood
count after initiation of AZA-therapy.
A recently published prospective randomized controlled trial
compared the efficacy of AZA and rituximab (RTX) in NMOSD.
It showed a significant decrease in mean ARR from 1 to 0.51
and a decrease in mean EDSS from 2.40 to 1.95 by AZA (178).
54% of the patient treated with AZA became relapse free after 1
year (178). A prospective study including 77 NMOSD patients
(183) and other retrospective studies (181, 184–186) showed
comparable results.
In a study by Jarius et al. 14 out of 17 MOG-patients (82%)
suffered from at least one attack while treated with AZA (33).
Attacks occurred mainly in patients that were not co-treated with
oral prednisone and during the first 6 months. This highlights the
need for co-treatment with oral prednisone until AZA reaches its
full efficacy.
Rituximab
RTX is a monoclonal Ab directed against the surface molecule
CD20 on B-lymphocytes. RTX leads to a depletion of CD20+B-
lymphocytes, which act as precursor cells of antibody producing
plasma cells (187). A thereby triggered reduction of antibody
formation is presumably the RTX mechanism of action.
The most frequently used dose regimen is the intravenous
administration of each 1,000mg with an interval of 2 weeks
followed by 6-monthly dosages of 1,000mg (179, 188).
Alternatively, initially 375 mg/m2 body surface every week
over a period of 4 weeks can be administered. As an alternative
to a fixed dosage regimen every 6 months, monitoring of
CD19+/CD20+ B-lymphocytes and administration of RTX in
the case of reconstitution of these cells is possible (189, 190).
Another option is the administration of RTX depending on
monitoring of CD27+ memory B-cells which might in some
cases allow to lower the cumulative RTX dose (191). An evidence
that one of these regimens has therapeutic superiority over the
other does not exist to date.
Before first administration, active infections like tuberculosis
or hepatitis B have to be excluded (192). An update of vaccination
status and anti-pneumococcal vaccination is recommended
(192).
Side effects include infusion-related symptoms like
pruritus, headache, rash or fever. To reduce the risk of these
symptoms, a premedication with an analgesic/antipyretic and an
antihistamine is recommended. The risk of infections and severe
skin reactions like the Lyell-syndrome or the Stevens-Johnson-
Syndrome is elevated. Cardiac symptoms e.g., arrhythmia or
cardiac insufficiency were reported (193). Moreover, neurologists
must be aware of hypogammaglobulinemia that may occur with
long-term RTX treatment (194).
In 2005, an open label study described for the first time a
significant reduction in disease activity in eight NMO patients
treated with RTX (195). Since then, an increasing number of
patients was treated with RTX. However, to date only a few
prospective studies investigating the effect of RTX on NMOSD
exist. The above mentioned study by Nikoo et al. showed a
reduction of the ARR by 83 percent as mean ARR decreased from
1.30 to 0.21 (178). Mean EDSS decreased from 3.55 to 2.56. Other
prospective and retrospective trials found significant reductions
of ARR to values between 0.1 and 0.46 in adult and pediatric
patients treated with RTX (181, 196–202). A further overview
on efficacy and safety profile of RTX in NMOSD is given in the
topical literature (203–205).
AZA and RTX are the most frequently used
immunosuppressants in NMOSD. With regards to ARR
and EDSS, comparison studies between both drugs seem to
suggest a superiority of RTX compared to AZA (178, 184).
Thus, currently RTX seems to be the most effective treatment in
NMOSD, although some studies describe a rebound in disease
activity shortly after RTX induction (199, 206). Treatment effect
does not seem to depend on AQP4-serostatus (96).
In MOG-EM, treatment with RTX led to a decline in relapse
rate in only 3 out of 9 patients (33). Most of the attacks
occurred shortly after RTX infusion. Some authors recommend
RTX as second-line-therapy if preventative treatment with
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low-dose prednisone or monthly intravenous immunoglobulins
(IVIG) is not effective (66). In patients with myelitis, RTX is
recommended from an earlier stage as a myelitis often leads to
severe residual deficits (66). Whether RTX is indeed less effective
in MOG-EM than in NMOSD has to be analyzed in further
studies (207).
Mycophenolate Mofetil
MMF is an immunosuppressant that inhibits the inosine
monophosphate dehydrogenase. Thereby, the synthesis of
guanosin nucleotide and subsequently, the proliferation of B- and
T-lymphocytes is inhibited. The administered daily dose ranges
between 750 and 3,000 mg/d (179, 208, 209).
The most common side effects are leucopenia, diarrhea,
vomiting and sepsis. The risk of malignomas can be increased
especially if MMF is combined with other immunosuppressants.
A retrospective observational study investigated the effect
of MMF in NMOSD and MOG-EM. 33/67 (49%) of the
patients were relapse-free, in 44/53 (83%) the EDSS improved
or stabilized (208). Other observational studies showed similar
results with proportions of relapse-free patients between 56 and
60% in NMOSD (210, 211) In comparison to AZA,MMF showed
fewer side effects with equal efficacy (211, 212). As in treatment
with RTX, response to MMF does not differ in dependence on
AQP4-serostatus (96).
In MOG-EM patients, a combined therapy with MMF and
steroids appeared to have a positive effect; however, this effect
diminished after steroid tapering (66). As MMF may take several
months to reach its full efficacy, add-on prednisone should be
tapered only very slowly.
Intravenous Immunoglobulins
Even less data is available for treatment with IVIG in
NMOSD. A small retrospective study including six patients
with NMO/NMOSD treated with IVIG 2–3- monthly showed a
decrease in ARR from 0.75 to 0.15 (213). One study investigated
IVIG treatment of acute NMOSD relapses (214), however, further
data on preventive IVIG therapy is lacking.
In a study by Ramanathan et al, 4 out of 7 MOG-EM
patients treated with IVIG were relapse-free (66). The authors
recommend prophylaxis with low-dose prednisone or monthly
IVIG with MMF or RTX as a next step for treating MOG-EM.
Jarius et al. reported data of one MOG-EM patient who was
relapse-free during 11 months of IVIG treatment and 12 months
after IVIG discontinuation (33).
Methotrexate
Methotrexate (MTX) is an analog of folate, acts as folate
antagonist and inhibits the dihydrofolate reductase. Hereby it
inhibits DNA and RNA synthesis and has an immunosuppressive
and anti-inflammatory effect. Side effects include gastrointestinal
symptoms like nausea or diarrhea, bone marrow depression and
an increase of liver enzymes.
Retrospective studies in NMOSD showed a decrease of ARR
between 64 and 87% (215–217). InMOG-EM,MTX led to disease
stabilization in 5/6 patients (33). Therefore, MTX seems to be
a treatment option in patients that do not respond to first-line-
therapy or suffer from side effects of other treatments (216).
MS Immunomodulatory Medication and
Rarer Treatment Options
Treatment with MS medications like interferon-beta, glatiramer
acetate, fingolimod, alemtuzumab, natalizumab, and presumably
also dimethyl fumarate is known to have no or even harmful
effects in NMOSD (181, 218–230). Similar results were found
in patients with MOG-EM which were treated with one
of these drugs for suspected MS (33); however, studies on
treatment effects of these drugs are even rarer than in
NMOSD.
Mitoxantrone is able to significantly reduce ARR in NMOSD
patients (231, 232), nevertheless, due to its cardio- and
myelotoxic side effects and the availability of alternatives
with fewer adverse events its use should be considered
very critically (233–235). Cyclophosphamide does not seem
to be effective in NMOSD (236). Data about the effects
of mitoxantrone or cyclophosphamide in MOG-EM are
missing.
Ongoing Studies
To date, various clinical trials are ongoing to investigate the
effect of new drugs in NMOSD. A placebo-controlled clinical trial
is testing the effect of inebelizumab (MEDI-551), a humanized
monoclonal antibody against CD19+ B-cells on NMOSD relapse
rate (237–239). The efficacy of B-cell-depleting therapy in
NMOSD is well known from treatment with RTX. AQP4-Ab
positive as well as AQP4-Ab negative patients with at least one
relapse during the last year or with at least two relapses during the
last 2 years before screening can be included in this study (237).
Another agent under investigation is eculizumab, a
monoclonal antibody inhibiting the complement protein
C5. There were encouraging findings from an open label study
where 12 out of 14 highly active patients became relapse-free
by eculizumab treatment (240, 241). A subsequent double-blind
placebo-controlled phase 3 trial aiming to enroll approximately
130 patients is now in the open-label extension stage (242).
Tocilizumab, an inhibitor of the IL-6 signaling pathway,
showed significant reduction of disease activity in two pilot
studies including in total 15 patients with high-active NMOSD
(243, 244). Moreover, it might be an option in NMOSD patients
with concomitant cancer or paraneoplastic syndrome (245).
To date, an open label randomized controlled trial comparing
tocilizumab and AZA is recruiting patients (246). Satralizumab
(SA237), a follow-on monoclonal antibody of tocilizumab,
is under investigation in a placebo-controlled double-blind
phase 3 study (247). Efforts to restore immune tolerance as
novel therapeutic endeavor are in preparation, however, various
technical and conceptual issues hamper prompt implementation
in clinical trials and practice (248, 249).
Further information on ongoing or completed (pilot) studies
as well as non-conventional treatment approaches, e.g., with
cetirizine, regulatory dentritic cells or autologous bone marrow
derived stem cells in NMOSD may be found at the website
https://clinicaltrials.gov and in current literature (188, 250, 251).
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SUMMARY
The diagnosis and treatment in NMOSD and MOG-EM require
special clinical expertise. The 2015 NMOSD diagnostic criteria
and the availability of antibody testing and MRI are the basis to
diagnose and differentiate NMOSD orMOG-EM. Early diagnosis
and initiation of adequate therapy are essential—at least in
seropositive patients–to avoid disease attacks and persistent
deficits. Long term immunosuppressive treatment, e.g., with RTX
or AZA, has emerged to be the most effective therapies to reduce
disease activity. Further therapeutic options, in particular various
monoclonal antibodies are currently under clinical investigation
in NMOSD.
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